 Selegiline
"Selegiline" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
| Descriptor ID |
D012642
|
| MeSH Number(s) |
D02.092.471.683.915
|
| Concept/Terms |
Selegiline- Selegiline
- Selegiline, (R)-Isomer
- Selegyline
- L-Deprenyl
Emsam- Emsam
- Bristol-Myers Squibb Brand of Selegiline
- Bristol Myers Squibb Brand of Selegiline
Zelapar- Zelapar
- Valeant Brand of Selegiline
- Selegiline Valeant Brand
|
Below are MeSH descriptors whose meaning is more general than "Selegiline".
Below are MeSH descriptors whose meaning is more specific than "Selegiline".
This graph shows the total number of publications written about "Selegiline" by people in this website by year, and whether "Selegiline" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Selegiline" by people in Profiles.
-
Hirschman KB, Joyce CM, James BD, Xie SX, Casarett DJ, Karlawish JH. Would caregivers of Alzheimer disease patients involve their relative in a decision to use an AD-slowing medication? Am J Geriatr Psychiatry. 2005 Nov; 13(11):1014-21.
-
Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005 May; 20(5):523-39.
-
Goetz CG, Leurgans S, Raman R. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
-
McDermott MP, Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, Golbe LI, Koller W, Lang AE, Olanow CW, et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol. 1995 Jun; 52(6):565-70.
-
Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989 Oct; 12(5):375-83.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|